The relationship between tumor-infiltrating lymphocytes, pathologic complete response, and event-free survival in patients with early-stage triple-negative breast cancer treated with the KEYNOTE-522 regimen in a real-world scenario
Introduction: Tumor-infiltrating lymphocytes (TILs) are established prognostic and predictive biomarkers in early-stage triple-negative breast cancer (eTNBC). The addition of pembrolizumab to neoadjuvant chemotherapy (NAC) improves outcomes, as demonstrated in the KEYNOTE-522 trial. The role of TILs in this setting war...